176Curated trials
Enterprise Evidence Report · NR-REPORT-V2.0
Sweden
Neuroscience Intelligence
Sweden neuroscience evidence report: current clinical, research, institution and source-linked intelligence.
Evidence rank #14 of 50 · Data maturity A · Research score 41.6 · Data confidence 100.0 / 100 · Snapshot 2026-10-12 03:34 UTC.
39Recruiting trials
253Publications
78Institutions
Executive interpretation
Sweden ranks #14 in the current NeuroRisk evidence-ranked market layer. This ranking summarizes indexed clinical, publication and institution evidence; it is not a probability of commercial success and not an investment recommendation.
Methodology status
Methodology NR-REPORT-V2.0. No synthetic ML confidence is presented as scientific probability. Counts and source links below are tied to the generation snapshot.
Methodology →Leading sponsors
Karolinska Institutet376 recruiting
Hoffmann-La Roche70 recruiting
Region Skane73 recruiting
Göteborg University60 recruiting
Merck Sharp & Dohme LLC65 recruiting
Pfizer50 recruiting
Uppsala University51 recruiting
Sahlgrenska University Hospital51 recruiting
Eli Lilly and Company40 recruiting
Umeå University40 recruiting
Disease activity
Alzheimers36trials
Parkinsons16trials
Adhd13trials
Depression10trials
Stroke10trials
Other Psychiatry7trials
Epilepsy7trials
Anxiety7trials
Other Neurology6trials
Pain Neuropathy6trials
Research institutions
Swedish Society of MedicineOpenAlexlinked institution
AstraZeneca (Sweden)OpenAlexlinked institution
Norra Älvsborgs LänssjukhusOpenAlexlinked institution
Danderyds sjukhusOpenAlexlinked institution
Region GävleborgOpenAlexlinked institution
Kristianstad UniversityOpenAlexlinked institution
Bolin Centre for Climate ResearchOpenAlexlinked institution
Royal Swedish Academy of SciencesOpenAlexlinked institution
European Atherosclerosis SocietyOpenAlexlinked institution
Sachs' Children and Youth HospitalOpenAlexlinked institution
Clinical evidence trail
NCT07550218Surfactant Administration Methods in Preterm Infants With RDS: A Swedish Cohort StudyRECRUITING
NCT07216703A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)RECRUITING
NCT07169747Safety, Therapeutic Potential, and Mechanisms of Two Psilocybin Doses, Administered With Psychological Support in Young Adults With Anorexia NervosaRECRUITING
NCT06966700A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)RECRUITING
NCT06952504A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)RECRUITING
NCT06937892Transdiagnostic Metacognitive Therapy Compared to Disorder-Specific Cognitive-Behavioral Therapy for Anxiety DisordersRECRUITING
NCT06906276Brain Activity During Complex Walking in People With Atypical Parkinsonian SyndromesRECRUITING
NCT06862193Effectiveness of Digital Intervention (HM4MH-app) on Perinatal Psychological WellbeingRECRUITING
Research evidence trail
PUBMEDFrom safety to agency: experiences of self-admission among patients with diverse mental health needs.2026-12-31
PUBMEDCandidate biomarkers in narcolepsy in H1N1-vaccinated cohorts: A proteomic and transcriptomic study.2026-12-01
PUBMEDParental support moderates the interaction of COMT and BDNF genotypes with early life adversity on problem gambling severity index scores among young adults.2026-12-01
PUBMEDAnalytical evaluation and method comparison of an orexin-A radioimmunoassay in cerebrospinal fluid: establishing a cut-off value for type 1 narcolepsy and exploring genetic and clinical characteristics.2026-12-01
PUBMEDDoing the groundwork at home, working through it together: patient experiences of blended cognitive therapy for PTSD in routine care.2026-12-01
PUBMEDConvictions among adolescents and young adults in Swedish substance use treatment: A latent class analysis.2026-12-01
PUBMEDPsychometric properties of the Swedish version of the PTSD checklist for DSM-5 (PCL-5) in a mixed trauma sample - examining internal consistency, convergent validity, latent structure, and screening performance.2026-12-01
PUBMEDDifferential contributions of PTSD symptom clusters and their associations with resilience in traumatized individuals with a refugee background.2026-12-01
PUBMEDDopamine D2/3 receptors and functional connectivity during fear extinction: A PET-fMRI study.2026-12-01
PUBMEDPatient experience and psychologists' attitudes toward AI in psychological treatment: A topic-modeling study.2026-12-01
PUBMEDImproving paediatric quality of care through a Sweden-Uganda twinning partnership - reflections on implementation and early experiences from the child thrive project.2026-12-01
PUBMED"Fidgety-like movements" in infants born extremely preterm and their relation to later neurodevelopmental outcome.2026-11-01
Sources and provenance
ClinicalTrials.gov provides NCT evidence. PubMed/NCBI and OpenAlex provide research metadata. OpenAlex links institutions. World Bank indicators are included only when an explicit source row and year exist. NeuroRisk transformations add normalization, ranking and graph connections.
Limitations
Indexed corpus counts are not guaranteed exhaustive global totals. Scores are comparative decision-support signals. This report is not medical advice, regulatory advice, patent clearance, an investment recommendation or a guarantee of outcome.